ESENSE-LAB IMPROVES THE QUANTITY AND QUALITY OF ITS REPLICATED...

ESENSE-LAB IMPROVES THE QUANTITY AND QUALITY OF ITS REPLICATED TERPENE PROFILES

 Achieves direct quantification of over 20 additional terpenes previously not detected by conventional methodologies

 Over 95% compatibility and accuracy achieved of the targeted medical cannabis strains

 10 commercial ready medical cannabis terpene profiles now of the highest compatibility available in the global market

Life sciences company eSense-Lab Ltd (“eSense” or the “Company”), (ASX:ESE), is pleased to report that it has identified an additional 20 terpenes and is now able to quantify more than 40 terpenes with the highest accuracy.

eSense’s proprietary plant profiling technology is used to generate comprehensive models (“profiles”) of targeted plants. The profile is then used to “reverse engineer” and reconstruct the terpene profile of that plant, using alternate natural sources, in a more cost effective and sustainable way. Terpenes are naturally occurring compounds (classified as phytochemicals) which account for the flavor and fragrance of plants, as well as many health benefits.

eSense previously announced a significant advancement in the Company’s yield and detection capabilities. The higher resolution capability has now enabled the direct quantification of greater than 20 additional terpenes, previously not detected by conventional methods.

From a commercial standpoint, the newly identified terpenes has allowed eSense to reconstruct 5 of the cannabis target strains terpene profiles, which are currently under distribution contract, to a compatibility and accuracy of over 95% of the target strains. When replicating the terpene profile of one single plant from one grower, eSense has the capability to achieve an accuracy of 99.9%. This has allowed the Company to achieve 95% accuracy when taking a sample of multiple strains and variations of terpenes across different growers of the same strain.

For the above mentioned cannabis profiles, the reconstructed formulations now utilize in excess of 40 unique terpenes (dependent on the unique characteristics of the strain), which is more than twice (2x) the terpene count of any other competitor.

The newly identified terpenes and advancement in the extraction and detection techniques has brought the Company’s production-ready profile number of 10 strains now to the highest compatibility for these targeted strains.

eSense is targeting the use of these profiles in the rapidly growing e-liquids market, used in e-cigarettes, vaporizers and diffusors.

Commenting on the further development, CEO Haim Cohen, said: “Our specialist scientific team continues to achieve new milestones within our proprietary technology. This latest achievement makes our terpene profiles of the highest compatibility available in the market, resulting in superior quality terpenes compared to what our peers can produce. We are receiving strong interest for our product and look forward to updating the market with our commercialization progress.”

Ends